GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESAIY) » Definitions » Net Interest Income

ESAIY (Eisai Co) Net Interest Income : $53 Mil (TTM As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Eisai Co Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Eisai Co's net interest income for the three months ended in Sep. 2024 was $8 Mil. Its net interest income for the trailing twelve months (TTM) ended in Sep. 2024 was $53 Mil.


Eisai Co Net Interest Income Historical Data

The historical data trend for Eisai Co's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Net Interest Income Chart

Eisai Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.79 7.22 5.98 37.21 56.18

Eisai Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.35 13.35 15.11 16.23 7.95

Eisai Co Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eisai Co Net Interest Income Related Terms

Thank you for viewing the detailed overview of Eisai Co's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co Business Description

Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co Headlines

From GuruFocus

Q2 2024 Eisai Co Ltd Earnings Presentation Transcript

By GuruFocus Research 02-13-2024

Q2 2022 Eisai Co Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Eisai Co Ltd Information Meeting Transcript

By GuruFocus Research 03-14-2024

Eisai Co Ltd Media and Investor Conference Transcript

By GuruFocus Research 02-13-2024

Full Year 2021 Eisai Co Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Eisai Co Ltd Clarity AD Study Briefing Transcript

By GuruFocus Research 02-13-2024